Evidence map›Paper›PMID 29538223›Full record

ArticleMedicine2018

You cannot miss it: Pancreatic mucoepidermoid carcinoma: A case report and literature review.

Hai-Jie Hu, Rong-Xing Zhou, Fei Liu, Jun-Ke Wang, Fu-Yu Li

Abstract readCase Reports
In one paragraph

Article in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hai-Jie HuDepartment of Biliary Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Rong-Xing Zhou
Fei Liu
Jun-Ke Wang
Fu-Yu Li

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationalePancreatic mucoepidermoid carcinoma (MEC) is a rare disease with no more than 10 cases reported in literature. The prognosis is poor and few patients can survival more than 1 year. PATIENT CONCERNS: We presented a case of patient manifested as left upper abdominal pain. Computed tomography demonstrated a low-density shadow measuring 2.1 × 2.4 cm situated at the transition area of neck and body of the pancreas with obscure boundary and irregular enhancement. The preoperative symptoms and imaging features were unspecific. DIAGNOSES: Pancreatic MEC.

interventionsCurative surgery of distal pancreatectomy was conducted. Postoperatively, the patient subsequently underwent 8 cycles of chemotherapy using cisplatin (25 mg/m) on day 1 to day 3; and gemcitabine (1000 mg/m) on day 1 and day 8, repeated every 21 days. OUTCOMES: The patient was monitored on a regular basis at our outpatient department and survived 23 months after surgery. LESSONS: Preoperative diagnosis of pancreatic MEC is difficult. Patients with pancreatic MEC may have a survival benefit from the multimodal treatment of curative surgery combined with chemotherapy.

Indexed as

Carcinoma, MucoepidermoidPancreasPancreatic NeoplasmsAntineoplastic AgentsChemotherapy, AdjuvantCisplatinDeoxycytidineDiagnosis, DifferentialDrug MonitoringGemcitabineHumansMaleMiddle AgedPancreatectomyTomography, X-Ray ComputedTreatment OutcomeAntineoplastic AgentsCisplatinDeoxycytidineGemcitabine

Identifiers

PMID29538223
PMCPMC5882400

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.